Design, synthesis and hypoglycemic activity of 3-methyl-1-phenyl-4-{4-[(5-methyl-2-phenyloxazol-4-yl)methoxy]benzylene(benzyl)}-2-pyrazol-5-one

Abstract

Based on the SAR (structure activity relationship) of TZDs (thiazolidinediones), 3-methyl-1-phenyl-2-pyrazoline-5-one was selected as a substitute for TZD. Compounds of 3-methyl-1-phenyl-4-{4-[(5-methyl-2-phenyloxazol-4-yl)methoxy]benzylene(benzyl)}-2-pyrazol-5-one were designed and synthesized to find some more hypoglycemic active agents and further investigate the SAR of this class of compounds. Butanedione monoxime reacted with (substituted) benzaldehyde via cyclization and chlorination to give 4-(chloromethyl)-5-methyl-2-phenyloxazole derivatives, which condensed with 4-hydroxybenzaldehyde or vanillin, and was followed by the Knoevenagel reaction with 3-methyl-1-phenyl-2-pyrazol-5-one to give compounds Ia–Ih. Compounds Ia–Ih were hydrogenated with Pd–C to give IIa–IIh, and their hypoglycemic activity was evaluated with a glucose oxidase kit and insulin load test on normal mice. Sixteen new target compounds were synthesized. All the compounds were characterized by ¹H NMR, IR, MS and elemental analysis. The preliminary pharmacological tests show that the compounds have good hypoglycemic activity and can enhance the action of insulin, especially Ib, Id and If.

References

1. Qian R L Theinsulin resistance and dysmetabolic syndromeChin J Diabetes 2006 14(1)23(in Chinese)
2. Lehman J M Moore L B Oliver-Smith T A Wilkinson W O Wilson T M Kliewer S A An antidiabetic thiazolidinedione is a high affinity ligandfor peroxisome proliferator activator receptor gammaJ Biol Chem 1995 2701295312956
3. Shinkai H Onogi S Tanaka M Shibata T Iwao M Wakitani K, Uchida I. Isoxazolidine-3,5-dione and noncyclic 1, 3-dicarbonyl compounds as hypoglycemic agentsJ Med Chem 1998 41(11)19271933
4. Henke B R Blanchard S G Brackeen M F Brown K K Cobb J E Collins J L Harrington W W Hashim M A Hull-Ryde E A Kaldor I Kliewer S A Lake D H Leesnitzer L M Lehmann J M Lenhard J M Orband-Miller L A Miller J F Mook R A Noble S A Oliver W Parks D J Plunket K D Szewczyk J R Willson T M N-(2-Benzoylphenyl)-L-tyrosine PPARg agonists.1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemicagentsJ Med Chem 1998 41(25)50205036
5. Liu S Yu J Y Oxygen free radicals with insulinresistance and type 2 diabetesJ Clin InternMed 2005 22(10)715717(in Chinese).
6. Evans J L Goldfine I D Maddux B A Grodsky G M Are oxidativestress-activated signaling pathways mediators of insulin resistanceand beta-cell dysfunction?Diabetes 2003 52(1)18
7. Takashi S Katsutoshi M Eiko I Hiroyuki T, Kanji M, Yutaka K, Yujiro Y. Studies on antidiabeticagents III 5-arylthiazolididine-2,4-diones as potent aldose reductaseinhibitorsChem Pharm Bull 1982 30(10)36013616
8. Kurogi Y Three-dimensionalquantitative structure-activity relationships (3D-QSAR) of antidiabeticthiazolidinedionesDrug Design Discov 1999 16109118
9. Yi X Guo Z R Study on 3D-QSAR of PPARγagonists with thiazolidinedione and arylketo-acid moietiesActa Pharmaceutica Sinica 2001 36(4)262268(in Chinese)
10. Turchi I J OxazolesHeterocyclic compoundsNew YorkJohn Wiley & Sons Publishers19861341
11. Goto Y Yamazaki M Hamana M Studies on azole compounds III. Reactions of oxazole N-oxideswith phosphoryl chloride and acetic anhydrideChem. Pharm. Bull. 1971 19(10)20502057
12. Michael S M Janet S Michael M Iwan G Brenda M Donald S Antihyperglycemicactivity of new 1,2,4-oxadiazolidine-3,5-dionesEur J Med Chem 2001 36(1)3142